Helena Martins

Helena Martins

Auto-generated profile, based on publicly available information

Helena Martins

A Instituto de Inovação e Investigação em Saúde (I3S), Universidade do Porto , Porto , Portugal and

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Closed access
TGTiago P. Guedes
Tiago P. Guedes
SMSofia Martins
Sofia Martins
MCMadalena Costa
Madalena Costa
SPSofia S. Pereira
Sofia S. Pereira
TMTiago Morais
Tiago Morais
MMMariana Monteiro
Mariana Monteiro

1 October 2016 in Amyloid
Verified
Journal Article
Closed access
PGPaula Gonçalves
Paula Gonçalves
HMHelena Martins
Helena Martins
SCSusete Costelha
Susete Costelha
LMLuis Maia
Luis Maia
MSMaria Joao Saraiva
Maria Joao Saraiva
Some TTR mutants target the central nervous system (CNS). Familial amyloid polyneuropathy (FAP) with leptomeningeal involvement has been described in 9% of transthyretin (TTR) mutations and in valine for methionine at position 30 (V30M) patients. These individuals present dementia, ataxia, brain hemorrhages and focal neurological episodes (FNEs). FNEs occurred also in V30M FAP patients with longer disease duration, who have undergone liver transplant to remove the source of plasma mutant TTR as a form of treatment. It is thus to expect that as better treatments for FAP emerge and prolong survival, meningeal-vascular CNS deposition will increase and need special therapies. Recently, we detected TTR meningeal-vascular deposition in a V30M TTR transgenic mouse model, opening new avenues of research to investigate selective treatments of this condition. Since pre-clinical studies with TTR siRNA therapeutics were shown to promote clearance of TTR non-fibrillar deposits in several organs and tissues, we investigated its effect on TTR meningeal-vascular deposition. We show that systemically administered TTR siRNA promoted TTR clearance in the extracellular matrix of meninges and brain blood vessels. Surprisingly, despite the striking decline of blood TTR, cerebrospinal fluid TTR levels were unaffected. Though this is reassuring because siRNA will not interfere with the neuroprotective role of TTR in the CNS, it raises new questions on therapeutical approaches for CNS ATTR.

16 March 2017 in Amyloid
Verified
Journal Article
Closed access
PGPaula Gonçalves
Paula Gonçalves
HMHelena Martins
Helena Martins
SCSusete Costelha
Susete Costelha
MSMaria Joao Saraiva
Maria Joao Saraiva

16 March 2017 in Amyloid
Verified
Journal Article
Closed access
CTCristina Teixeira
Cristina Teixeira
SCSusete Costelha
Susete Costelha
HMHelena Sofia Martins
Helena Sofia Martins
ATAnabela Teixeira
Anabela Teixeira
MSMaria Joao Saraiva
Maria Joao Saraiva